文献速递消化道肿瘤放疗胸部肿瘤放疗

西妥昔单抗联合术前放化疗治疗局部晚期食管鳞状细胞癌与高长期生存率相关:一项前瞻性Ib/II期试验的成熟结果

The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial.
PubMed 文献 · Radiother Oncol · 2019-02-04

这项Ib/II期研究评估西妥昔单抗联合标准术前放化疗治疗可切除局部晚期食管癌的安全性和疗效。64例患者接受治疗,5年生存率38%,鳞癌患者病理完全缓解率55%对20%、局部控制率96%对74%、5年生存率58%对25%,均优于腺癌。作者认为该方案可行,鳞癌患者获益更多。

要点

  • 64例可切除局部晚期食管癌患者接受西妥昔单抗联合术前放化疗,5年生存率38%。
  • 鳞癌患者病理完全缓解率55%对腺癌20%(p=0.015),局部控制率96%对74%(p<0.001),5年生存率58%对25%(p=0.011)。
  • 3级及以上毒性发生率72%,毒性死亡2例(3%),术后死亡8例(14%)。

核心结论

  • 作者认为,在标准术前放化疗基础上加用西妥昔单抗是可行的,R0切除率、病理完全缓解率和局部控制率令人鼓舞。
  • 鳞癌患者从加用西妥昔单抗中获益更多。

研究设计与样本

  • 前瞻性Ib/II期研究,纳入可切除局部晚期食管癌患者(T2-3N0-1M0、T1-3N1M0或T1-3N0-1M1A),共64例接受治疗。

主要发现

  • 64例中60例完成放化疗,中位年龄65岁,男性占66%,腺癌/鳞癌比例为61%/39%,95%为T3、67%为N1。
  • 3级及以上毒性发生率72%,毒性死亡2例(3%);5-氟尿嘧啶最大耐受剂量为1000 mg/m2/天。
  • 临床完全缓解率33%;55例接受手术者中R0切除51例(93%),病理完全缓解18例(33%),术后死亡8例(14%)。
  • 全部患者5年生存率38%;鳞癌患者病理完全缓解率55%对腺癌20%(p=0.015),局部控制率96%对74%(p<0.001),5年生存率58%对25%(p=0.011)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This phase IB/II study evaluated the safety and efficacy of the addition of cetuximab to standard preoperative chemoradiotherapy (CRT) in locally advanced esophageal cancer (LAEC). METHODS: Patients (pts) with resectable LAEC (T2-3N0-1M0, T1-3N1M0 or T1-3N0-1M1A) received an induction cycle of cisplatin 100 mg/m2, day 1, and 5-fluorouracil (5-FU) 1000 mg/m2/day, days 1-5, followed 4 weeks later by radiotherapy, 50.4 Gy, given with 2 cycles of cisplatin 75 mg/m2 and escalating doses of 5-FU, days 1-4 and 29-32. Pts received 10 weekly infusions of cetuximab, 250 mg/m2, with a loading dose, 400 mg/m2. Surgery was planned 6-8 weeks after CRT. RESULTS: 64 pts were treated and 60 completed CRT. Median age was 65 years and 66% were males. Adenocarcinoma/squamous ratio was 61%/39%. Tumors were advanced: 95% T3 and 67% N1. Grade ≥3 toxicities occurred in 72%, with two (3%) toxic deaths. The 5-FU maximal tolerated dose (MTD) was 1000 mg/m2/day. Clinical complete response rate was 33%. Of the 55 operated pts, R0 resection was achieved in 51 (93%) and pathological complete response (pCR) in 18 (33%), with 8 (14%) postoperative deaths. The 5-year survival rate for all pts was 38%. Pts with squamous histology had higher pCR (55% vs 20%, p = 0.015), local control (96% vs. 74%, p < 0.001) and 5-year survival (58% vs 25%, p = 0.011) rates. CONCLUSIONS: This study suggests that the addition of cetuximab to standard preoperative CRT is feasible. R0, pCR and local control rates are encouraging. Pts with squamous cell tumors benefited more from the addition of cetuximab.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Brenner B, Purim O, Gordon N, et al. The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial. Radiother Oncol. 2019. PMID: 31005227. doi:10.1016/j.radonc.2019.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。